Share on StockTwits
 

Stock analysts at Maxim Group lifted their price target on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from $88.00 to $92.00 in a report issued on Monday, StockRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective indicates a potential upside of 8.48% from the company’s current price.

A number of other analysts have also recently weighed in on VRTX. Analysts at TheStreet upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 14th. Analysts at UBS AG upgraded shares of Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Monday, January 6th. They now have a $99.00 price target on the stock, up previously from $84.00. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Vertex Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $93.53.

Vertex Pharmaceuticals (NASDAQ:VRTX) opened at 84.81 on Monday. Vertex Pharmaceuticals has a one year low of $43.69 and a one year high of $89.96. The stock has a 50-day moving average of $80.24 and a 200-day moving average of $74.43. The company’s market cap is $19.996 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, January 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.07. The company had revenue of $351.20 million for the quarter, compared to the consensus estimate of $221.08 million. During the same quarter in the previous year, the company posted ($0.35) earnings per share. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $-2.31 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.